Can you summarize the current role of DTE in managing persons with hypothyroidism, and the approach to identifying the 10%-20% of persons on LT4 monotherapy who, because of symptomatic shortfalls, may be appropriate for combination therapy?

Can you summarize the current role of DTE in managing persons with hypothyroidism, and the approach to identifying the 10%-20% of persons on LT4 monotherapy who, because of symptomatic shortfalls, may be appropriate for combination therapy?

Can you summarize the current role of DTE in managing persons with hypothyroidism, and the approach to identifying the 10%-20% of persons on LT4 monotherapy who, because of symptomatic shortfalls, may be appropriate for combination therapy?


Created by

CMEducation Resources IQ&A Thyroid Hormone Replacement Medical Intelligence Zone

Presenter

Christine Kessler, MN, ANP-BC, CNS, BC-ADM, FAANP

Christine Kessler, MN, ANP-BC, CNS, BC-ADM, FAANP

Founder, Nurse Practitioner Metabolic Medicine AssociatesCo-Chair, Metabolic & Endocrine Disease Summit (MEDS) King George, Virginia